• PMH14 A CASE-CONTROL STUDY ON SECOND-GENERATION ANTIDEPRESSANT USE IN PATIENTS WITH BIPOLAR DISORDER

    May 1, 2005, 00:00

  • PHPI4 MAKING A CASE FOR EMPLOYING SOCIETAL PERSPECTIVE IN THE EVALUATION OF MEDICAID FORMULARIES

    May 1, 2005, 00:00

  • PHP7 PRESCRIPTION DRUG NONCOMPLIANCE AMONG TRICARE BENEFICIARIES AT MILITARY PHARMACIES

    May 1, 2005, 00:00

  • CV4 CUMULATIVE EXPOSURE TO CYCLOOXYGENASE-2 INHIBITORSAND CARDIOVASCULAR RISK

    May 1, 2005, 00:00

  • PCN12 ESTIMATING COSTS OF UNCONTROLLED CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING AMONG WORKING-AGE CANCER PATIENTS

    May 1, 2005, 00:00

  • PMH48 SYSTEMATIC REVIEW ON RELAPSE AND ANTIPSYCHOTIC NON-ADHERENCE IN SCHIZOPHRENIA

    May 1, 2005, 00:00

  • PPN7 CONFIRMATORY FACTOR ANALYSIS OF THE BECK DEPRESSION INVENTORY

    May 1, 2005, 00:00

  • PDB45 QUALITY OF LIFE (SF12), CLINICAL OUTCOMES, AND COMORBID CONDITIONS IN PATIENTS WITH TYPE-2 DIABETES- A POPULATION STUDY

    May 1, 2005, 00:00

  • PHP2I TRENDS IN PHARMACEUTICAL SPENDING GROWTH IN THE UNITED STATES, 1998-2002

    May 1, 2005, 00:00

  • PHP26 THE CURRENT AND FUTURE OF PHARMACOECONOMICS IN UKRAINE

    May 1, 2005, 00:00

  • PIN20 IMPROVEMENT IN ANTIMALARIAL DRUGS ACCESS- RESULTS OF A PROGRAM PERFORMED IN YAOUNDE

    May 1, 2005, 00:00

  • PCV27 AN ECONOMIC ANALYSIS OF EZETIMIBE/SIMVASTATIN COMPARED TO USUAL CARE WITH STATIN MONOTHERAPY

    May 1, 2005, 00:00

  • DRUG-ELUTING VERSUS BARE-METAL CORONARY STENTS- 6-MONTH CLINICAL AND ECONOMIC OUTCOMES OF A CONTROLLED STUDY FOR THE REDUCTION OF CORONARY RESTENOSIS

    May 1, 2005, 00:00

  • PNL30 FORECASTING THE IMPACT OF ADDING A NEW DRUG ON FORMULARY USING MEDICAL CLAIMS DATA AND CLINICAL LITERATURE- A CASE STUDY OF INSOMNIA TREATMENT

    May 1, 2005, 00:00

  • PCN14 IS COMBINED ANDROGEN BLOCKADE WITH BICALUTAMIDE COST-EFFECTIVE COMPARED WITH COMBINED ANDROGEN BLOCKADE WITH FLUTAMIDE?

    May 1, 2005, 00:00

  • PNL3 THE COST-EFFECTIVENESS OF QUETIAPINE FOR ALZHEIMERS DISEASE IN COMMUNITY DWELLING PATIENTS

    May 1, 2005, 00:00

  • PMH30 OUTCOME ANALYSIS OF A MULTI-LEVEL INTERVENTION PROGRAM TO IMPROVE ANTIDEPRESSANT MEDICATION ADHERENCE

    May 1, 2005, 00:00

  • PHP49 BRIEF SUMMARY FORMATS OF DTCATO IMPROVE CONSUMER COMPREHENSION

    May 1, 2005, 00:00

  • PDB35 FACTOR ANALYSIS AND PRELIMINARY VALIDATION OF INSULIN DELIVERY SYSTEM QUESTIONNAIRE

    May 1, 2005, 00:00

  • PNL9 CARE COSTS OF PARTIAL REFRACTORY EPILEPSY IN MEXICO

    May 1, 2005, 00:00

  • PCN18 OPIOID USE IN A LARGE NATIONAL HOSPICE POPULATION- EXAMINATION OF CANCER VERSUS NON-CANCER PATIENTS

    May 1, 2005, 00:00

  • PSK9 PREVALENCE OF CHRONIC HAND DERMATITIS AND ITS IMPACT ON PATIENT-REPORTED OUTCOMES IN A MANAGED CARE POPULATION

    May 1, 2005, 00:00

  • Disclosure Information

    May 1, 2005, 00:00

  • PDB28 AN EVALUATION OF A DISEASE MANAGEMENT PROGRAM FOR ADULT DIABETICS IN A MEDICAID POPULATION

    May 1, 2005, 00:00

  • PDB1 PREVALENCE OF CO-MORBID CONDITIONS AND CONCOMITANT MEDICATION USE AMONG TYPE-2 DIABETES PATIENTS IN A STATE MEDICAID POPULATION

    May 1, 2005, 00:00

  • PNL32 PHYSICIAN AND PATIENT DETERMINANTS OF THE TREATMENT OF SLEEP DIFFICULTIES IN OUTPATIENT SETTINGS IN THE UNITED STATES

    May 1, 2005, 00:00

  • PCV29 PREDICTORS OF COMPLIANCE AND PERSISTENCE TO STATIN THERAPY AMONG TEXAS MEDICAID PATIENTS

    May 1, 2005, 00:00

  • RS2 ASSESSING HEALTH-RELATED QUALITY OF LIFE USING THE SF-I2V2 FOR PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

    May 1, 2005, 00:00

  • PIN28 THE COST-EFFECTIVENESS OF PREVENTING MOTHER-TO-CHILD TRANSMISSION OF HIV IN CHINA

    May 1, 2005, 00:00

  • PMH3 QUALITY-ADJUSTED LIFE YEARS GAINED WITH BUPRENORPHINE TREATMENT FOR OPIATE ADDICTION

    May 1, 2005, 00:00

  • PNL21 FUNCTIONAL LIMITATIONS, MENTAL HEALTH, AND RESOURCE USE ASSOCIATED WITH THE HEALTH-RELATED QUALITY OF LIFE OF PATIENTS WITH RESTLESS LEGS SYNDROME

    May 1, 2005, 00:00

  • FMI PRESCRIPTION DRUG COST-SHARING AND ANTICOAGULANT DRUG USE-UNINTENDED EFFECTS OF THINNER BENEFITS

    May 1, 2005, 00:00

  • PNL5 DRUG PERSISTENCY OF TWO CHOLINESTERASE INHIBITORS-RIVASTIGMINE VERSUS DONEPEZIL AMONG ELDERLY PATIENTS WITH ALZHEIMERS DISEASE

    May 1, 2005, 00:00

  • PMH65 IMPACT OF ATYPICAL AGENTS ON OUTCOMES OF CARE IN SCHIZOPHRENIC PATIENTS

    May 1, 2005, 00:00

  • PUK14 FACTORS INFLUENCING THE ROUTE OF ADMINISTRATION FOR EPOETIN TREATMENT AMONG U.S. HEMODIALYSIS PATIENTS

    May 1, 2005, 00:00

  • PMH29 THE EFFECT OF RAISING THREE TIER COPAYMENTS ON SSRI COMPLIANCE RATES

    May 1, 2005, 00:00

  • PMH8 A REVIEW OF THE ECONOMIC BURDEN OF ADHD

    May 1, 2005, 00:00

  • MC4 CHOOSING BETWEEN SFI2/SF-36 PREFERENCE-BASED ALGORITHMS FOR COST-UTILITY ANALYSIS

    May 1, 2005, 00:00

  • PCV30 MONITORING OF LIPID LEVELS AND ADVERSE EVENTS AMONG TEXAS MEDICAID PATIENTS ON STATIN THERAPY

    May 1, 2005, 00:00

  • MH3 SUPPORT FOR CLASSIFICATION OF DEPRESSION OUTCOMES INTO LONGITUDINAL PATTERNS- EVIDENCE FROM A POPULATION-BASED STUDY OF THE ELDERLY

    May 1, 2005, 00:00

  • PMH33 DRUG UTILIZATION AND MARKET-SHARE COMPETITION AMONG ANTIDEPRESSANT MEDICATIONS IN US MEDICAID PROGRAMS

    May 1, 2005, 00:00

  • PRS13 HEALTH CARE EXPENDITURE AND UTILIZATION FOR PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

    May 1, 2005, 00:00

  • PMH57 ELECTRONIC MONITORING OF ANTIPSYCHOTIC ADHERENCE OF OUTPATIENTS WITH SCHIZOPHRENIA AND SCHIZOAFFECTIVE DISORDER AND ASSOCIATION WITH SYMPTOMS, QUALITY OF LIFE AND COGNITION

    May 1, 2005, 00:00

  • PNL17 EFFECT OF IMMUNOMODULATORYTHERAPYAND OTHER FACTORS ON PRODUCTIVITY IN MS

    May 1, 2005, 00:00

  • PAS4 PATTERNS OF PHARMACOTHERAPY UTILIZATION AMONG CHILDREN AND ADOLESCENTS WITH MULTIPLE ASTHMA-RELATED MORBID EVENTS ENROLLED IN A MEDICAID PROGRAM

    May 1, 2005, 00:00

  • PNL34 SEDATIVE HYPNOTICS EMPLOYED TO TREAT PATIENTS WITH AND WITHOUT INSOMNIA COMPLAINTS IN THE NATIONAL AMBULATORY MEDICAL CARE SURVEY- 1997-2002

    May 1, 2005, 00:00

  • PMH12 PREVALANCE AND COST OF BIPOLAR DISORDER AND TREATMENT WITHIN A MANAGED CARE ORGANIZATION

    May 1, 2005, 00:00

  • PCV36 CHOLESTEROL GOAL ATTAINMENT IN DYSLIPIDEMIC TREATED PATIENTS AND INCIDENCE OF CARDIOVASCULAR EVENTS IN CLINICAL PRACTICE

    May 1, 2005, 00:00

  • CS6 TREATMENT OF INSTITUTIONALIZED PATIENTS WITH ALZHEIMERS DISEASE WITH QUETIAPINE- A COST-EFFECTIVENESS EVALUATION

    May 1, 2005, 00:00

  • PMH2 COSTS OF TREATING CRISIS-PRONE SCHIZOPHRENIA PATIENTS

    May 1, 2005, 00:00

  • INI COST EFFECTIVENESS OF HIVTREATMENT INNOVATIONS OF GREATER EFFICACY THAN HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART)

    May 1, 2005, 00:00

  • PMC10 AN INTERNET-BASED EDUCATIONAL INTERVENTION TO INCREASE KNOWLEDGE- A RAPID, EFFICIENT, AND EFFECTIVE METHOD

    May 1, 2005, 00:00

  • PCV44 PHYSICAL INACTIVITY IS ASSOCIATED WITH INCREASED HEALTH CARE USE AND EXPENDITURES IN INDIVIDUALS WITH HYPERTENSION

    May 1, 2005, 00:00

  • MCI WHY DO DIFFERENT MODELS COME TO DIFFERENT CONCLUSIONS?- A STUDY OF 8 COST-EFFECTIVENESS ANALYSES COMPARING COX-2 SPECIFIC INHIBITORS (COXIBS) AND NON STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS)

    May 1, 2005, 00:00

  • PDB32 THE RELATIONSHIP BETWEEN PATIENTS TYPE OF PAYMENT AND PRESCRIPTION DRUG COSTS FOR DIABETIC PATIENTS

    May 1, 2005, 00:00

  • PHP27 QUALITY OF ECONOMIC MODELS IN DOSSIERS SUBMITTED UNDERTHEAMCP FORMAT

    May 1, 2005, 00:00

  • PIN26 VALIDATION OF A HEALTH-RELATED QUALITY OF LIFE INSTRUMENT FOR HEPATITIS B PATIENTS IN SINGAPORE

    May 1, 2005, 00:00

  • PMC32 USING MARKOV MATRICES TO INTEGRATE RISK/BENEFIT CONSIDERATIONS OF HEALTH CARE INTERVENTIONS EVALUATED USING HEALTH-RELATED QUALITY OF LIFE INSTRUMENTS

    May 1, 2005, 00:00

  • PIHI INCORPORATING OF HERD IMMUNITY INTO PHARMACOECONOMIC EVALUATION OF PNEUMOCOCCAL CONJUGATE VACCINE PNC-7

    May 1, 2005, 00:00

  • QLI IS RELIEF WORTH THE RISK? RISK-BENEFIT PREFERENCES FOR TREATMENTS FORVASOMOTOR SYMPTOMS

    May 1, 2005, 00:00

  • PMC20 RELATIONSHIP BETWEEN PATIENT SATISFACTION AND PERCEIVED HEALTH STATUS

    May 1, 2005, 00:00

  • PDB41 VALIDATION OF THE GERMAN TRANSLATION OF THE NORFOLK QOL-DN, NERVE FIBER SPECIFIC QUESTIONNAIRE

    May 1, 2005, 00:00

  • PEY6 MEDICAL CARE COSTS OF PRIMARY OPEN-ANGLE GLAUCOMA IN THE UNITED STATES-A NATIONAL ESTIMATE USING THE MEDICAL EXPENDITURE PANEL SURVEY

    May 1, 2005, 00:00

  • PEN1 COST SAVINGS ASSOCIATED WITH FINER DOSING INCREMENTS THROUGH THE USE OF NORDITROPIN NORDIFLEX IN THE UNITED STATES

    May 1, 2005, 00:00

  • PMH64 USE OF THE CAREGIVER STRAIN QUESTIONNAIRE IN AN INTERNATIONAL STUDY

    May 1, 2005, 00:00

  • CV7 9301 COST-EFFECTIVENESS OF LONG-TERM THERAPY WITH CLOPIDOGREL FOLLOWING PERCUTANEOUS CORONARY INTERVENTION- A SWEDISH ANALYSIS OF THE CREDO-TRIAL

    May 1, 2005, 00:00

  • PCN17 ASSESSMENT OF BREAST CANCER KNOWLEDGE, SCREENING BEHAVIOR, RISK PERCEPTIONS, AND

    May 1, 2005, 00:00

  • DB2 ECONOMIC CONSEQUENCES OF CHOICE OF DIABETES THERAPY IN A MEDICAID POPULATION

    May 1, 2005, 00:00

  • PRS1 PULMONOLOGISTS PERCEPTIONS OF ANEMIA IN COPD- A SURVEY

    May 1, 2005, 00:00

  • PDB2 IMPACT OF DEPRESSION ON INCIDENCE OF TYPE-2 DIABETES IN A STATE MEDICAID POPULATION

    May 1, 2005, 00:00

  • PMC13 VALUE OF ADDING MEDICAL CLAIMS DATA TO THE PHARMACY-BASED MODELS PREDICTING FUTURE HEALTH CARE COSTS AND JUMPS IN COSTS

    May 1, 2005, 00:00

  • PCN15 RESOURCE UTILIZATION AMONG PROSTATE CANCER PATIENTS WITH BONE PAIN

    May 1, 2005, 00:00

  • FM2 CHANGES IN ADHERENCE FOLLOWING A CO-PAY CHANGE FOR ASTHMA AND DIABETES THERAPIES

    May 1, 2005, 00:00

  • INI COMPARISON OF RISK FACTORS FOR BLOOD STREAM CANDIDEMIA AND BACTEREMIA IN HOSPITALIZED PATIENTS

    May 1, 2005, 00:00

  • PUK2 THE COST-EFFECTIVENESS OF SUBSTITUTING DARBAPOETIN FOR EPOETIN-WHEN ECONOMIC MODELLING DOES NOT PREDICT REAL LIFE RESULTS

    May 1, 2005, 00:00

  • PDB43 ASSOCIATIONS AMONG VISUAL IMPAIRMENT, STAGE OF DIABETIC RETINOPATHY AND QUALITY OF LIFE (EQ-5D)

    May 1, 2005, 00:00

  • PUK13 PREDICTORS OF MEDICATION ADHERENCE AND ASSOCIATED HEALTH CARE COSTS IN AN OLDER POPULATION WITH DETRUSOR OVERACTIVITY- A LONGITUDINAL COHORT STUDY

    May 1, 2005, 00:00

  • PCV46 USE OF NON-US SUPPLIED PHARMACEUTICALS IN THE TREATMENT OF HYPERTENSION IN A LATINO POPULATION IN LOS ANGELES COUNTY, CA, USA

    May 1, 2005, 00:00

  • QL2 NEW WEIGHTS FOR OLD- A SCALE OF VALUES FOR EQ-5D HEALTH STATES

    May 1, 2005, 00:00

  • PIN12 INFANTILE GASTROENTERITIS IN THE COMMUNITY- A COST OF ILLNESS STUDY

    May 1, 2005, 00:00

  • HP6 CHOLESTEROL GOAL ATTAINMENT AMONG CHD PATIENTS IN HONG KONG

    May 1, 2005, 00:00

  • PNL13 COST-EFFECTIVENESS OF ELETRIPTAN VERSUS ZOLMITRIPTAN- RESULTS FROM A RANDOMIZED CONTROLLED TRIAL

    May 1, 2005, 00:00

  • PIHI3 COST-EFFECTIVENESS ANALYSIS OF BENIGN PROSTATIC HYPERPLASIA (BPH) TREATMENTS

    May 1, 2005, 00:00

  • PNL28 THE PREVALENCE OF INSOMNIA IN PATIENTS WITH DRUG DEPENDENCY OR ABUSE

    May 1, 2005, 00:00

  • PPN5 TYPES OF PROBLEMS ASSOCIATED WITH INTRAVENOUS PATIENT-CONTROLLED ANALGESIA (IV PCA) INFUSION PUMPS-AN ANALYSIS OF THE MANUFACTURER AND USER FACILITY DEVICE EXPERIENCE (MAUDE) DATABASE

    May 1, 2005, 00:00

  • PSK6 INTERPRETING SCORES ON THE QUALITY OF LIFE INDEX FOR ATOPIC DERMATITIS (QOLIAD)

    May 1, 2005, 00:00

  • PHPI7 MODELING THE COST AND UTILIZATION OF MAIL ORDER VS. COMMUNITY PHARMACY IN A MEDICAID POPULATION

    May 1, 2005, 00:00

  • PDB27 IMPACT OF A DIABETES CARE PROJECT ON MEDICATION UTILIZATION AND ADHERENCE

    May 1, 2005, 00:00

  • PCV41 PATIENT EDUCATION AND ADHERENCE AND HYPERTENSION CONTROL IN TWO ACADEMIC MEDICAL CENTER PRIMARY CARE PRACTICES

    May 1, 2005, 00:00

  • PPN3 SUMMARY OF HOSPITAL LOGISTICS ASSOCIATED WITH INTRAVENOUS PATIENT-CONTROLLED ANALGESIA (IV PCA) FOR ACUTE POSTOPERATIVE PAIN MANAGEMENT

    May 1, 2005, 00:00

  • Economic and Utilization Outcomes Associated with Choice of Treatment for Venous Thromboembolism in Hospitalized Patients

    May 1, 2005, 00:00

  • PCN13 SURVIVAL AND COST FOLLOWING BREAST CANCER RECURRENCE- ESTIMATES FROM SEER-MEDICARE DATA

    May 1, 2005, 00:00

  • PMH34 IMPACT OF RELABELING ON NEFAZODONE PRESCRIBING- A RISK MINIMIZATION EVALUATION

    May 1, 2005, 00:00

  • PNL20 RESTLESS LEGS SYNDROME PLACES A SUBSTANTIAL BURDEN ON THE HEALTH-RELATED QUALITY OF LIFE OF US AND EUROPEAN PATIENTS

    May 1, 2005, 00:00

  • PNL25 COST AND USE OF PARKINSONISM-INDUCING DRUGS AMONG MEDICARE BENEFICIARIES

    May 1, 2005, 00:00

  • PMH23 ASSESSING VENLAFAXINE, SERTRALINE, OR PLACEBO TREATMENT ON IMPROVEMENT IN GENERAL LIFE FUNCTIONING AMONG DEPRESSED PATIENTS

    May 1, 2005, 00:00

  • PHP28 THE EFFECT OF CORPORATE STRUCTURE ON FORMULARY DESIGN- THE CASE OF LARGE INSURANCE COMPANIES

    May 1, 2005, 00:00

  • PCV19 TRENDS IN PHARMACY USE AMONG VETERANS WITH CHRONIC HEART FAILURE (1999-2002)

    May 1, 2005, 00:00

  • PNL2 THE COST-EFFECTIVENESS OF DONEPEZILAND RIVASTIGMINE IN THE TREATMENT OF ALZHEIMERS DISEASE IN THAILAND PRIVATE HOSPITAL

    May 1, 2005, 00:00

  • PCV52 A MULTI-COUNTRY HEALTH ECONOMIC EVALUATION OF N-3 POLYUNSATURATED FATTY ACIDS (PUFA) IN THE SECONDARY PREVENTION AFTER MI

    May 1, 2005, 00:00

  • PCV51 SHORT AND LONG-TERM COST-EFFECTIVENESS OF EARLY AND SUSTAINED DUAL ORAL ANTIPLATELET THERAPY WITH CLOPIDROGREL FOLLOWING PERCUTANEOUS CORONARY INTERVENTION-A CANADIAN ECONOMIC ANALYSIS

    May 1, 2005, 00:00

  • PGI9 MODELING RISK OF GI EVENTS AMONG MEDICAID NSAID USERS, USING PROPENSITY SCORES

    May 1, 2005, 00:00

  • PSR7 DISABILITY MEASURES IN STROKE- SCORE CONVERSION BETWEEN THE BARTHEL INDEX AND THE MOTOR COMPONENT OF FUNCTIONAL INDEPENDENCE MEASURE FOR PRACTITIONER

    May 1, 2005, 00:00

  • PCN21 RETRANSFORMATION OF ESTIMATED LOG-TRANSFORMED COSTS WHEN THE ERRORS PRESENT HETEROSKEDASTICITY

    May 1, 2005, 00:00

  • PINI OUTPATIENT COMMUNITY-ACQUIRED PNEUMONIA IN NON-ELDERLY ADULTS- TREATMENT AND OUTCOMES

    May 1, 2005, 00:00

  • PAR10 SATISFACTION WITH PAIN MEDICATION AND INTENTION TO COMPLY WITH TREATMENT- A STRUCTURAL EQUATION MODEL IN RHEUMATOID ARTHRITIS PATIENTS

    May 1, 2005, 00:00

  • PHP22 IMPACT OF HEALTH INSURANCE ON HEALTH-RELATED QUALITY OF LIFE

    May 1, 2005, 00:00

  • PMH31 THE RELATIVE PERFORMANCE OF NEWER ANTIDEPRESSANTS IN A MEDICAID POPULATION

    May 1, 2005, 00:00

  • PIN11 A COST-EFFECTIVENESS ANALYSIS MODEL FOR TREATMENT OF CANDIDIASIS AND INVASIVE ASPERGILLOSIS IN MEXICO

    May 1, 2005, 00:00

  • QL4 THE CONTENT VALIDITY OF CLINICIAN DERIVED PATIENT REPORTED OUTCOMES (PRO) MEASURES- THE ROLAND MORRIS DISABILITY QUESTIONNAIRE

    May 1, 2005, 00:00

  • PMC23 TRANSLATABILITY ASSESSEMENT- A NEW APPROACH TO INTERNATIONAL QUESTIONNAIRE DEVELOPMENT

    May 1, 2005, 00:00

  • PMC27 PATIENTS PERSPECTIVES OF TREATMENT SATISFACTION- A QUALITATIVE RESEARCH EVALUATION

    May 1, 2005, 00:00

  • HP5 FINANCIAL BARRIERS TO MEDICATION USE IN CHILDREN WITH ASTHMA- AN ANALYSIS OF PRIVATE SECTOR PRESCRIPTION MEDICATION CLAIMS

    May 1, 2005, 00:00

  • PMC17 THE UK EQ-5DINDEX- AN EVALUATION OF FACE VALIDITY IN HOSPITAL TREATED SUBJECTS

    May 1, 2005, 00:00

  • PPN4 PARENTS PERCEPTION OF THE SAFETY OF PEDIATRIC NON-PRESCRIPTION DRUGS-ACETAMINOPHEN AS AN EXAMPLE

    May 1, 2005, 00:00

  • PCN19 VARIATIONS IN INPATIENT PROSTATE CANCER TREATMENT IN FLORIDA

    May 1, 2005, 00:00

  • PSK4 THE LIFETIME COST OF TREATING SEVERE PSORIASIS WITH HOME UVB THERAPY

    May 1, 2005, 00:00

  • PUK8 THE DIRECT COSTS OF STRESS URINARY INCONTINENCE TREATMENT AMONG WOMEN IN A MEDICAID POPULATION

    May 1, 2005, 00:00

  • PMH58 THE ELECTRONIC SCHIZOPHRENIA TREATMENT ADHERENCE REGISTRY-E-STAR- BASELINE RESULTS FOR GERMANY

    May 1, 2005, 00:00

  • PMH17 COMPARING PROPENSITY SCORE AND DIFFERENCE-IN-DIFFERENCE METHODS- SECOND-GENERATION ANTIDEPRESSANT USE FOR BIPOLAR DISORDER

    May 1, 2005, 00:00

  • PMH28 A COST-EFFECTIVENESS ANALYSIS OF ESCITALOPRAM AND SERTRALINE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER

    May 1, 2005, 00:00

  • PAR4 A REVIEW OF TOTAL COST BURDEN OF FIBROMYALGIA

    May 1, 2005, 00:00

  • PDB7 CLINICAL JUDGMENT OF DRUG THERAPY FOR TYPE-2 DIABETES PATIENTS AND RESULTS OF HBA1C TESTS

    May 1, 2005, 00:00

  • POS2 ALENDRONATE AND HORMONE REPLACEMENT THERAPY (HRT) IN THE PREVENTION OF OSTEOPOROTIC FRACTURE IN THE DEPARTMENT OF DEFENSE (DOD)- AN ANALYSIS USING NET-BENEFIT REGRESSION

    May 1, 2005, 00:00

  • PMH51 COST-EFFECTIVENESS EVALUATION OF LONG-ACTING RISPERIDONE

    May 1, 2005, 00:00

  • PINI0 ECONOMIC ANALYSIS OF VACCINATION WITH MENACTRA IN THE US

    May 1, 2005, 00:00

  • PHPI5 PHARMACOECONOMIC EDUCATION AT MEDICAL SCHOOLS IN TURKEY

    May 1, 2005, 00:00

  • PNLI ASSESSMENT OF COMORBIDITY AND INCIDENCE RATE OF ALZHEIMERS DISEASE IN THE CALIFORNIA MEDICAID (MEDI-CAL) PROGRAM

    May 1, 2005, 00:00

  • PHP20 EFFECT OF A PHARMACY BENEFIT CHANGE ON ACCURACY OF PRESCRIPTION DATABASES DAYS SUPPLYVARIABLE

    May 1, 2005, 00:00

  • PDB24 ECONOMIC IMPACT OF CARDIOVASCULAR CO-MORBIDITY IN PATIENTS WITH TYPE-2 DIABETES

    May 1, 2005, 00:00

  • PUK4 A COMPARISON OF TOTAL DIRECT MEDICAL COSTS AMONG PATIENTS RECEIVING AGENTS USED IN THE PHARMACOLOGIC MANAGEMENT OF OVERACTIVE BLADDER

    May 1, 2005, 00:00

  • PDB12 EFFECT OF GLYCEMIC CONTROL ON HEALTH CARE COSTS

    May 1, 2005, 00:00

  • PIN24 ACUTE SINUSITIS OUTCOMES AND CHARGES- A COMPARISON OF TWO FLUOROQUINOLONES

    May 1, 2005, 00:00

  • PHM2 IMPACT OF ANEMIA ON IN-HOSPITAL FALLS- A MATCHED CASE-CONTROL STUDY

    May 1, 2005, 00:00

  • CVI DISCRETE EVENT SIMULATION TO ESTIMATE COST-BENEFIT OF PREVENTING SUDDEN CARDIAC DEATHS WITH AN IMPLANTABLE CARDIOVERTER DEFIBRILLATOR (ICD) VS. AMIODARONE IN FRANCE

    May 1, 2005, 00:00

  • PDB44 IS DIABETES KNOWLEDGE ASSOCIATED WITH HEALTH-RELATED QUALITY OF LIFE AMONG ENGLISH-SPEAKING SUBJECTS WITH DIABETES IN SINGAPORE?

    May 1, 2005, 00:00

  • PUK19 ESTABLISHING THE CONTENT VALIDITY OF THE URINARY SENSATION SCALE (USS)

    May 1, 2005, 00:00

  • PHP44 USING THE TRANSTHEORETICAL MODEL (TTM) TO EXPLAIN, PREDICT OR INFLUENCE PHYSICIAN PATIENT CARE BEHAVIOR- A SYSTEMATIC REVIEW

    May 1, 2005, 00:00

  • PIN29 COST OF THERAPY FORARV NAIVE HIV-INFECTED PATIENTS- FOSAMPRENAVIR / RITONAVIR VERSUS NELFINAVIR

    May 1, 2005, 00:00

  • PSR4 FREQUENCY OF INR TESTING IN MEDICARE BENEFICIARIES AT HIGH RISK FOR STROKE

    May 1, 2005, 00:00

  • PDB40 THE USE OF DIABETES PREVENTION PROGRAM RESULTS TO MODEL COST-EFFECTIVENESS OF THE INTERVENTION IN A MORE GENERALIZED HYPOTHETICAL POPULATION

    May 1, 2005, 00:00

  • PDB8 PREVALENCE OF DIABETES MELLITUS AND TREATMENT PATTERNS BASED ON CLASSIFICATION OF BODY MASS INDEX AMONG ADULTS

    May 1, 2005, 00:00

  • PNL27 PREVALENCE OF INSOMNIA AMONG PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN A LARGE DATABASE

    May 1, 2005, 00:00

  • PSR1 COST-EFFECTIVENESS OF CLOPIDOGREL VERSUS ASPIRIN IN THE PREVENTION OF ISCHEMIC EVENTS IN STROKE AND TIA PATIENTS- A FOUR-EUROPEAN COUNTRY ANALYSIS

    May 1, 2005, 00:00

  • PMC2 A SYSTEMATIC REVIEW OF ECONOMIC EVALUATIONS OF GENETIC TESTING TECHNOLOGIES

    May 1, 2005, 00:00

  • PUK12 ADHERENCE WITH MEDICATIONS USED TO TREAT OVERACTIVE BLADDER IN A MANAGED CARE POPULATION.

    May 1, 2005, 00:00

  • PST2 INPATIENT RESOURCE UTILIZATION AND COSTS OF PROCEDURES IMPLANTING DRUG-ELUTING STENTS IN COMPLEX CASES-THE ARRIVE REGISTRY

    May 1, 2005, 00:00

  • PNL29 COST-EFFECTIVENESS OF LONGER-TERM TREATMENT WITH ESZOPICLONE 3MG IN ADULTS WITH PRIMARY INSOMNIA

    May 1, 2005, 00:00

  • PUK17 PREVALENCE, DEMOGRAPHICS, AND PHARMACOLOGICAL TREATMENT PATTERNS OF OVERACTIVE BLADDER IN A MANAGED CARE POPULATION

    May 1, 2005, 00:00

  • PMS2 EVALUATION OF AN AUTOMATED SYSTEM FOR PRIOR AUTHORIZATION-A COX-2 INHIBITOR EXAMPLE

    May 1, 2005, 00:00

  • PEN6 EVALUATION OF THE ASSOCIATION BETWEEN HEIGHT AND HEALTH-RELATED UTILITY (EQ5DINDEX)

    May 1, 2005, 00:00

  • MSI PARENTERAL PARECOXIB FOLLOWED BY ORAL VALDECOXIB AFTER MAJOR GENERAL SURGERY REDUCES OPIOID CONSUMPTION AND OPIOID-RELATED SYMPTOMS

    May 1, 2005, 00:00

  • PCV24 WHAT IS THE RELEVANCE OF AGE GROUPS IN SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS? A COST-UTILITY ANALYSIS IN MEXICO

    May 1, 2005, 00:00

  • PSR6 STROKE RECURRENCE AND PERSISTENCE ON DRUG THERAPY IN A MEDICAID POPULATION

    May 1, 2005, 00:00

  • PDB21 HEALTH CARE RESOURCE UTILIZATION AND COST IN TYPE-2 DIABETES PATIENTS RECEIVING COMBINATION SULFONYLUREA (SU) AND ROSIGLITAZONE (RSG)- THE RESULT TRIAL

    May 1, 2005, 00:00

  • PHP33 UTILITY OF MEDIA ON HEALTH PROMOTION AND SELFMEDICATION

    May 1, 2005, 00:00

  • PCN10 ECONOMIC IMPACT OF PROSTATE-SPECIFIC ANTIGEN DOUBLING TIME IN PATIENTS WITH HORMONEREFRACTORY PROSTATE CANCER

    May 1, 2005, 00:00

  • PCV7 HEALTH CARE RESOURCE UTILIZATION AND COST OF ATRIAL FLUTTER PATIENTS

    May 1, 2005, 00:00

  • CSI ECONOMIC BURDEN OF OSTEOPOROSIS-RELATED FRACTURES IN MEDICAID

    May 1, 2005, 00:00

  • PDB4 GLYCEMIC RESPONSE TO PIOGLITAZONE THERAPY IN AFRICAN-AMERICAN AND LATINO PATIENTS WITH TYPE-2 DIABETES

    May 1, 2005, 00:00

  • PIN13 ANNUAL COST FOR THE TREATMENT OF PATIENTS HOSPITALIZED WITH METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS IN THE UNITED STATES

    May 1, 2005, 00:00

  • PIN8 ECONOMIC EVALUATION OF INTRAVENOUS ITRACONAZOLE IN PRESUMED SYSTEMIC FUNGAL INFECTIONS IN NEUTROPENIC PATIENTS IN KOREA

    May 1, 2005, 00:00

  • PCV53 COST ANALYSIS ON ANTICOAGULANT DRUG MARKET

    May 1, 2005, 00:00

  • PIH22 NEW INSIGHTS INTO THE PLACEBO EFFECTS- A CASE STUDY OF THE EFFECTIVENESS OF HORMONE THERAPY ON THE FREQUENCY OF HOT FLASHES

    May 1, 2005, 00:00

  • PMH26 COST-EFFECTIVENESS ANALYSIS OF ESCITALOPRAM IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER IN TURKEY

    May 1, 2005, 00:00

  • PNL10 PSYCHOMETRIC EVALUATION OF EPILEPSY-SPECIFIC QUALITY OF LIFE INSTRUMENTS

    May 1, 2005, 00:00

  • PRS9 ADHERENCE TO RESPIRATORY MEDICATIONS IN VA PATIENTS WITH CHRONIC LUNG DISEASE

    May 1, 2005, 00:00

  • PMH4 COST-EFFECTIVENESS OF ALPRAZOLAM IN ANXIETY DISORDERS

    May 1, 2005, 00:00

  • PCV9 COST-EFFECTIVENESS OF AMIODARONE TO PREVENT ATRIAL FIBRILLATION AFTER CARDIAC SURGERY

    May 1, 2005, 00:00

  • PAS9 CHOOSING AMONG DIFFERENT TYPES OF MATCHING TECHNIQUES

    May 1, 2005, 00:00

  • HP4 POTENTIALLY INAPPROPRIATE MEDICATION PRESCRIBING FOR ELDERLY AMBULATORY PATIENTS IN REGIONE EMILIA ROMAGNA, ITALY

    May 1, 2005, 00:00

  • PIHI2 RELATIONSHIP BETWEEN QUALITY OF LIFE AND INAPPROPRIATE DRUG USE- A RETROSPECTIVE ANALYSIS IN AN ELDERLY POPULATION

    May 1, 2005, 00:00

  • DBI ESTIMATION OF THE FINANCIAL IMPACT OF OBESITY ON THE NATIONAL HEALTH SERVICE AND SOCIETY IN THE UNITED KINGDOM

    May 1, 2005, 00:00

  • PDB25 DEPRESSION IN PATIENTS WITH TYPE-2 DIABETES- IMPACT ON UTILIZATION PATTERNS AND ADHERENCE TO ORAL HYPOGLYCEMIC AGENTS

    May 1, 2005, 00:00

  • PHPI3 TRENDS IN THE PREVALENCE OF INAPPROPRIATE PRESCRIBING AMONG ELDERLY MEDICARE BENEFICIARIES, 1992-2001

    May 1, 2005, 00:00

  • PGI6 UTILIZATION, RE-TREATMENT, AND COST OF DIFFERING LENGTHS OF H. PYLORI TREATMENT REGIMENS FROM US HEALTH CARE CLAIMS DATABASES

    May 1, 2005, 00:00

  • CV3 ONE-YEAR COSTS FORACUTE CORONARY SYNDROME- AN INTEGRATED HEALTHCARE SYSTEM PERSPECTIVE

    May 1, 2005, 00:00

  • HP2 EFFECTS OF PATIENTS BELIEFS ABOUT MEDICATIONS ON NON-ADHERENCE TO CHRONIC MEDICATIONS

    May 1, 2005, 00:00

  • POB5 COST EFFECTIVENESS OF SIBUTRAMINE IN THE LONG-TERM OUTCOMES OF SIBUTRAMINE EFFECTIVENESS ON WEIGHT STUDY

    May 1, 2005, 00:00

  • IN3 COSTS OF DELIVERING ADULT INFLUENZA VACCINATION IN NON-TRADITIONAL SETTINGS

    May 1, 2005, 00:00

  • PSK10 THE NEGATIVE IMPACT OF PSORIASIS ON WORK PRODUCTIVITY

    May 1, 2005, 00:00

  • PER2 PROCESS EVALUATION OF THE IMPLEMENTATION OF OTITIS MEDIA GUIDELINES IN AN INTEGRATED DELIVERY SYSTEM

    May 1, 2005, 00:00

  • PDB29 THE EFFECT OF INSULIN TREATMENT ON HEALTH CARE UTILIZATION IN TYPE-II DIABETES

    May 1, 2005, 00:00

  • PCV18 USE OF -BLOCKERS FOR TREATING HEART FAILURE AMONG THE ELDERLY IN BRITISH COLUMBIA, CANADA, 1993-2001

    May 1, 2005, 00:00

  • PCN4 ECONOMIC EVALUATION OF INTRAVENOUS (IV) ZOLEDRONIC ACID VS. OTHER IV BISPHOSPHONATES IN THE PREVENTION OF BONE COMPLICATIONS IN BREAST CANCER PATIENTS WITH BONE METASTASES- A UK BUDGET IMPACT ANALYSIS

    May 1, 2005, 00:00

  • PAR11 THE IMPACT OF DEPRESSION ON RHEUMATOID ARTHRITIS PATIENT QUALITY OF LIFE

    May 1, 2005, 00:00

  • PDB5 CAN USE OF GLITAZONES REDUCE THE RISK OF ALZHEIMERS DISEASE IN PATIENTS WITH DIABETES?

    May 1, 2005, 00:00

  • PPN6 RETROSPECTIVE ANALYSIS OF DRUG UTILIZATION PATTERNS IN CANCER AND NON-CANCER PATIENTS TRANSDERMAL FENTANYL

    May 1, 2005, 00:00

  • PPN10 PATIENT SATISFACTION WITH PAIN MANAGEMENT 28 DAYS AFTER TOTAL KNEE ARTHROPLASTY

    May 1, 2005, 00:00

  • PDB46 WILLINGNESS-TO-PAY FOR INHALED INSULIN-A CANADIAN PERSPECTIVE

    May 1, 2005, 00:00

  • PSK7 USING DUANS SMEARING ESTIMATOR TO MEASURE COST OF CHRONIC HAND DERMATITIS (CHHD) IN A MASSACHUSETTS HEALTH MAINTENANCE ORGANIZATION (HMO)

    May 1, 2005, 00:00

  • PMC11 WHICH ONE IS LOGICAL? LOGIT OR RARE EVENT LOGIT (RE-LOGIT)

    May 1, 2005, 00:00

  • PDB30 TREATMENT PATTERNS AMONG PATIENTS WITH DIABETES ON METFORMIN AND SULFONYLUREA COMBINATION THERAPY

    May 1, 2005, 00:00

  • PRS12 RACIAL DISPARITIES IN PREDICTORS OF HEART FAILURE IN MEDICAID PATIENTS WITH COPD

    May 1, 2005, 00:00

  • PCN5 BUDGET IMPACT ANALYSIS OF INTRAVENOUS (IV) ZOLEDRONIC ACID VS. ORAL IBANDRONATE OR IV GENERIC PAMIDRONATE IN THE PREVENTION OF BONE COMPLICATIONS IN BREAST CANCER PATIENTS WITH BONE METASTASES- A UK NHS PERSPECTIVE

    May 1, 2005, 00:00

  • PIN2 EFFECT OF INAPPROPRIATE ANTIBIOTIC THERAPY ON CLINICAL OUTCOMES OF PATIENTS WITH PSEUDOMONAS AERUGINOSA BACTEREMIA

    May 1, 2005, 00:00

  • PMH43 IMPACT OF A PSYCHOEDUCATION PROGRAM ON HEALTH STATUS OF SEVERE AND PERSISTENTLY MENTALLY ILL

    May 1, 2005, 00:00

  • PCV8 TOTAL HEALTH CARE COSTS OF PATIENTS WITH CHRONIC NON-VALVULAR ATRIAL FIBRILLATION BEFORE AND AFTER TIA, ISCHEMIC STROKE OR MAJOR BLEED

    May 1, 2005, 00:00

  • PIN4 IMPACT OF EMPIRIC ANTIFUNGAL THERAPY ON MORTALITY IN HOSPITALIZED PATIENTS WITH BLOODSTREAM CANDIDEMIA

    May 1, 2005, 00:00

  • PCN8 THE COST-EFFECTIVENESS OF PROSTATE-SPECIFIC ANTIGEN SCREENING FOR PROSTATE CANCER DETECTION

    May 1, 2005, 00:00

  • CS3 IMPACT OF ESTIMATION TECHNIQUE ON MEDICAL COST ESTIMATES FOR OVERACTIVE BLADDER TREATMENTS

    May 1, 2005, 00:00

  • PEY8 PATIENT-REPORTED VISUAL FUNCTION IN LOW-VISION POPULATIONS (NEI-VFQ)-AN ANALYSIS WITH COMPARISONS OF READING PERFORMANCE, CONTRAST SENSITIVITY, SCOTOMA TESTING, AND VISUAL ACUITY

    May 1, 2005, 00:00

  • PMC22 DEVELOPING SYMPTOM-BASED QUESTIONNAIRES FOR DIAGNOSTIC SCREENING

    May 1, 2005, 00:00

  • PHP38 A CENTRAL COMPUTERIZED DRUG PRIOR-AUTHORIZATION PROCESS IN A MANAGED CARE SETTING IN ISRAEL

    May 1, 2005, 00:00

  • PHM6 A HIDDEN EPIDEMIC AMONG ACUTE CARE INPATIENTS- ECONOMIC AND CLINICAL IMPACTS OF ANEMIA IN SELECTED CHRONIC DISEASES

    May 1, 2005, 00:00

  • PMH56 STARTING DOSE AND PERSISTENCE FOR ZIPRASIDONE USERS IN MEDICAID

    May 1, 2005, 00:00

  • PAS8 A DYAD APPROACH TO QUALITY OF LIFE MEASUREMENT IN CHILDREN WITH ASTHMA

    May 1, 2005, 00:00

  • PCV3 UTILIZATION OF RECOMMENDED DRUG THERAPY IN ACUTE CORONARY SYNDROME

    May 1, 2005, 00:00

  • PIN22 HOSPITALIZED COMMUNITY ACQUIRED PNEUMONIA- A THREE YEAR REVIEW OF PATIENT FACTORS ASSOCIATED WITH PROLONGED LENGTH OF STAY

    May 1, 2005, 00:00

  • PHPI2 SOCIAL AND ECONOMIC FACTORS AFFECTING INTENTIONAL PRESCRIPTION DRUG NON-COMPLIANCE AMONG NOVA SCOTIA SENIORS

    May 1, 2005, 00:00

  • DB3 COST-EFFECTIVENESS OF DETECTION OF CAD BY MYOCARDIAL PERFUSION IMAGING IN ASYMPTOMATIC PATIENTS WITH DIABETES

    May 1, 2005, 00:00

  • PDB9 FACTORS ASSOCIATED WITH A LOWER GLYCOSYLATED HEMOGLOBIN A1C (A1C) IN A DIABETIC LATINO POPULATION

    May 1, 2005, 00:00

  • PHP3I- SAFETY NET ACTIVITIES STRUCTURAL CHARACTERISTICS MEMBERSHIP IN LOCAL HOSPITAL SYSTEMS

    May 1, 2005, 00:00

  • Cost-Effectiveness of Face-to-Face Smoking Cessation Interventions- A Dynamic Modeling Study

    May 1, 2005, 00:00

  • PGI7 MANAGING CROHNS DISEASE- USE AND COST OF INPATIENT, EMERGENCY DEPARTMENT AND OBSERVATION

    May 1, 2005, 00:00

  • PPN8 DEVELOPMENT OF DIFFERENT LANGUAGE VERSIONS OF A US BACK PAIN QUESTIONNAIRE

    May 1, 2005, 00:00

  • PHP34 AN ASSESSMENT OF THE ASSOCIATION BETWEEN UNDERLYING WORKER MEDICAL CONDITIONS AND WORKER ABSENTEEISM IN THE US

    May 1, 2005, 00:00

  • PCV23 EVALUATING THE DIAGNOSTIC VALIDITY OF ADMINISTRATIVE CLAIMS DATA FOR COMMON CHRONIC DISEASES

    May 1, 2005, 00:00

  • PCV54 ECONOMIC AND HUMANISTIC BURDEN OF POST-ACUTE MYOCARDIAL INFARCTION HEART FAILURE IN GERMANY

    May 1, 2005, 00:00

  • PRS14 RISK-BENEFIT ASSESSMENT OF TELITHROMYCIN FOR THE TREATMENT OF CAP USING QUALITY-ADJUSTED DAYS (QAD) LOST

    May 1, 2005, 00:00

  • PHP10 UTILIZATION AND COSTS OF A 90-DAY RETAIL PROGRAM IN COMPARISON WITH 30-DAY RETAIL AND MAIL SERVICES

    May 1, 2005, 00:00

  • IN2 SIMULATION OF A PROPOSED TRIAL TO EVALUATE THE COST-EFFECTIVENESS OF USING A COMBINATION REGIMEN FOR THE TREATMENT OF ACUTE SINUSITIS

    May 1, 2005, 00:00

  • PMH16 MEASURING THE EFFECT OF A POLICY CHANGE IN MONTHLY PRESCRIPTION LIMIT ON HEALTH CARE UTILIZATION AND EXPENDITURE- A CONTROLLED COMPARISON OF OLS AND PANEL ESTIMATION

    May 1, 2005, 00:00

  • PNL8 USING A TOUCHTONE TELEPHONE TO COLLECT DATA FROM ELDERLY CAREGIVERS OF PATIENTS WITH ALZHEIMERS DISEASE

    May 1, 2005, 00:00

  • PEN3 HEALTH STATUS VALUES (UTILITIES) FOR THE SWEDISH POPULATION- A MODEL BASED ON THE EQ-5D ASSESSMENT OF ACTUAL HEALTH STATE, USING JACKKNIFE METHOD AND MULTIPLE REGRESSION ANALYSIS

    May 1, 2005, 00:00

  • PMC19 IMPROVING THE SCALING PROPERTIES OF THE PSYCHOLOGICAL GENERAL WELL-BEING SCALE (PGWB)

    May 1, 2005, 00:00

  • DB5 BODY MASS INDEX (BMI) AND TRENDS IN GP CONSULTATIONS AND PRESCRIBING- A UK NHS PERSPECTIVE

    May 1, 2005, 00:00

  • PIN5 COST ANALYSIS OFA FEBRILE NEUTROPENIA ALGORITHM WITH RESPECT TO EMPIRICAL ANTIFUNGAL THERAPY IN ADULT HEMATOLOGY/ONCOLOGY PATIENTS

    May 1, 2005, 00:00

  • PCV38 A COMPARISON OF THE ELIXHAUSER AND CHARLSON INDICES TO CONTROL FOR CONFOUNDING IN HEALTH OUTCOMES STUDIES

    May 1, 2005, 00:00

  • PMH40 QUALITY-ADJUSTED REMISSION FREE DAYS- AN EXTENDED Q-TWIST APPLICATION IN MAJOR DEPRESSION DISORDER

    May 1, 2005, 00:00

  • CN4 EXPLICIT VALUATION OF PASS-THROUGH TECHNOLOGIES UNDER MEDICARE- IS IT FEASIBLE OR DESIRABLE]

    May 1, 2005, 00:00

  • PCN24 HANDLING MISSING PATIENT REPORTED OUTCOMES (PRO) DATA FOR PREMATURE WITHDRAWALS FROM CLINICAL TRIALS OF SEVERE DISEASES

    May 1, 2005, 00:00

  • PNL11 AN ECONOMIC EVALUATION OFTRIPTAN PRODUCTS FOR MIGRAINE

    May 1, 2005, 00:00

  • PIN31 USE OF THE SYMPTOMS DISTRESS MODULE IN AN INTERNATIONAL STUDY

    May 1, 2005, 00:00

  • PAR12 ABATACEPT (CTLA4IG) IN COMBINATION WITH METHOTREXATE DEMONSTRATES SUSTAINED IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES OVER TWO YEARS IN RHEUMATOID ARTHRITIS PATIENTS WITH INADEQUATE RESPONSE TO METHOTREXATE

    May 1, 2005, 00:00

  • PMC6 ACCURATE AND RAPID PREDICTION OF DRUG PLAN EXPENDITURE WHILE PLANNING REIMBURSEMENT CHANGES USING POLICY SIMULATION

    May 1, 2005, 00:00

  • PHP8 EVALUATION OF A CLINICAL PHARMACOKINETIC MONITORING SYSTEM

    May 1, 2005, 00:00

  • PDB13 COST OF DIABETES COMPLICATIONS IN FRANCE, GERMANY, ITALY AND SPAIN

    May 1, 2005, 00:00

  • PMH5 ECONOMIC BURDEN OF GENERALIZED ANXIETY DISORDER (GAD) AND OTHER ANXIETY DISORDERS

    May 1, 2005, 00:00

  • PMC18 HEALTH UTILITIES INDEX (HUI) ON-LINE QUESTIONNAIRE SYSTEM- CRITERION VALIDITY OF MULTI- AND SINGLE-ATTRIBUTE UTILITY SCORES

    May 1, 2005, 00:00

  • PMH61 COMPARISON OF OUTCOMES REPORTED BY INDIVIDUALS WITH SCHIZOPHRENIA RESIDING IN THE COMMUNITY AND OBJECTIVE OUTCOMES REPORTED BY CAREGIVERS

    May 1, 2005, 00:00

  • PNL16 DEVELOPMENT OF A UNIQUE INTERNET PHONE BASED SYSTEM TO CAPTURE MIGRAINE TREATMENT OUTCOMES

    May 1, 2005, 00:00

  • PIHI4 USE OF SILDENAFIL CITRATE IN NON-ADHERENT PATIENTS WITH CVD, DIABETES OR DEPRESSION

    May 1, 2005, 00:00

  • PCV45 ANTIHYPERTENSIVE THERAPY AFTER ALLHAT- ARE MORE PATIENTS STARTING WITH DIURETICS?

    May 1, 2005, 00:00

  • PCN3 TIME TO CANCER DIAGNOSIS (TDX) IN YOUNG AMERICANS DEPENDS ON TYPE OF CANCER AND HEALTH INSURANCE STATUS

    May 1, 2005, 00:00

  • PMH44 PERCEPTION OF SIDE EFFECTS MEDICATION ADHERENCE AND QUALITY OF LIFE IN PSYCHIATRIC PATIENTS

    May 1, 2005, 00:00

  • PEN2 COST-UTILITY OF NORDITROPIN (R-DNA SOMATROPIN) IN CHILDREN WITH GROWTH HORMONE DEFICIENCY

    May 1, 2005, 00:00

  • PMC31 AT WHAT COST? A REVIEW OF DRUG ACQUISITION COST ISSUES IN MODELLED ECONOMIC EVALUATIONS.

    May 1, 2005, 00:00

  • PMH19 TREATMENT ADHERENCE WITH ANTIPSYCHOTICS AMONG BIPOLAR AND MANIC PATIENTS

    May 1, 2005, 00:00

  • PIH3 DIRECT COST OF TREATMENT FOR AUTISM SPECTRUM DISORDER IN CALIFORNIA MEDICAID

    May 1, 2005, 00:00

  • PCV55 PREVALENCE OF METABOLIC SYMDROME IN KOREAN AMERICANS IN THE UNITED STATES

    May 1, 2005, 00:00

  • PIH20 COST OF ILLNESS STUDY OF NAUSEA AND VOMITING OF PREGNANCY IN CANADA

    May 1, 2005, 00:00

  • PMH35 THE MAIN AND INTERACTION EFFECTS OF PATIENT AND PHYSICIAN CHARACTERISTICS IN INFLUENCING THE PRESCRIBING OF ANTIDEPRESSANTS

    May 1, 2005, 00:00

  • PHP25 ANALYSIS OF PRESCRIBING PATTERN WITH THE NEGATIVE LIST FORMULARY SYSTEM IN KOREA

    May 1, 2005, 00:00

  • MS2 CARDIOVASCULAR RISK FACTORS AT BASELINE IN USERS OF COXIBS COMPARED TO USERS OF NSAIDS

    May 1, 2005, 00:00

  • PDB37 HEALTH ECONOMIC COMPARISON OF INSULIN ASPART, A FAST-ACTING INSULIN ANALOG, VERSUS HUMAN INSULIN AS MEALTIME INSULIN IN THE TREATMENT OF TYPE-1 DIABETES IN AUSTRIAN, DANISH, DUTCH, FINNISH, FRENCH, GERMAN, NORWEGIAN, SPANISH AND SWEDI ...

    May 1, 2005, 00:00

  • PRS7 PHARMACOECONOMIC ANALYSIS OF TIOTROPIUM THERAPY IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASES IN HONG KONG V A PRELIMINARY REPORT

    May 1, 2005, 00:00

  • PDB34 NEEDLESTICK INJURY IN NURSES CARING FOR PATIENTS WITH DIABETES

    May 1, 2005, 00:00

  • PCN1 META-ANALYSIS OF THE DIAGNOSTIC ACCURACY OF SCREENING TESTS FOR COLORECTAL CANCER

    May 1, 2005, 00:00

  • PMH1 HEALTH CARE AND WORKLOSS COSTS OF OPIOID ABUSE AMONG AN EMPLOYED POPULATION IN THE US

    May 1, 2005, 00:00

  • POB1 COMPARISON OF WEIGHT REDUCTION AND SATISFACTION OF ORLISTAT AND SIBUTRAMINE

    May 1, 2005, 00:00

  • POB3 PREVALENCE TRENDS OF OVERWEIGHT AND OBESITY AND TREATMENT PATTERNS FOR WEIGHT CONTROL IN THE US POPULATION

    May 1, 2005, 00:00

  • POB6 COSTS OF OBESITY IN THE UNITED STATES AND EUROPE- A REVIEW OF THE LITERATURE

    May 1, 2005, 00:00

  • PMC33 BRIDGING BEYOND REGRESSION-ARTIFICIAL NEURAL NETWORK IN MAPPING FROM SF-36 TO HEALTH UTILITY

    May 1, 2005, 00:00

  • CV8 ASSOCIATION BETWEEN LONG-TERM USE OF NSAIDS/ COX-2 INHIBITORSAND CARDIOVASCULAR RISK-A RETROSPECTIVE ANALYSIS USING THE VETERAN AFFAIRS (VA) DATABASE

    May 1, 2005, 00:00

  • PEY7 COST OF GLAUCOMA TO THE CALIFORNIA MEDICAID (MEDI-CAL) PROGRAM BETWEEN 1995 AND 2002

    May 1, 2005, 00:00

  • PHP46 IMPACT OF PRESCRIBING GUIDELINES FOR INPATIENT ANTICOAGULATION

    May 1, 2005, 00:00

  • PSU2 ELECTIVE SURGERIES IN THE US- RISK FACTORS, COST, AND OUTCOMES

    May 1, 2005, 00:00

  • POS7 VALIDATION STUDY OF THE OSTEOPOROSIS PATIENT SATISFACTION QUESTIONNAIRE (OPSAT-Q)

    May 1, 2005, 00:00

  • PMH60 THE ELECTRONIC SCHIZOPHRENIA TREATMENT ADHERENCE REGISTRY-E-STAR- DATA QUALITY ASSURANCE GATE KEEPING METHODS

    May 1, 2005, 00:00

  • PCV26 COST-EFFECTIVENESS OF EZETIMIBE CO-ADMINISTRATION IN CHD PATIENTS NOT AT GOAL WITH CURRENT STATIN THERAPY IN HONG KONG

    May 1, 2005, 00:00

  • PIHI7 EVALUATION OF TADALAFIL AND VARDENAFIL TREATMENT PATTERNS IN PRIOR SILDENAFIL USERS

    May 1, 2005, 00:00

  • PCV48 ASSESSMENT OF THE VALIDITY OF TWO CLAIMS-BASED ALGORITHMS IN IDENTIFYING HYPERTENSIVE PATIENTS

    May 1, 2005, 00:00

  • PCV47 USE OF ANTIHYPERTENSIVE MEDICATIONS AMONG VETERANS NEWLY DIAGNOSED WITH HYPERTENSION

    May 1, 2005, 00:00

  • PIN30 ANEMIA IN HIV/AIDS PATIENTS IN THE HAART ERA CLINICAL AND HUMANISTIC IMPACT

    May 1, 2005, 00:00

  • PMH62 VALUATION OF SCHIZOPHRENIA-RELATED HEALTH STATES BY THE GENERAL POPULATION USING THE AQOL, TIME TRADE-OFF AND VISUAL ANALOGUE SCALES

    May 1, 2005, 00:00

  • PMH45 HISTORY OF SUBSTANCE ABUSE ASSOCIATED WITH POOR PROGNOSIS IN THE TREATMENT OF SCHIZOPHRENIA- RESULTS FROM A CLINICAL TRIAL DATABASE

    May 1, 2005, 00:00

  • PDB16 THE ASSOCIATION BETWEEN DIABETES RELATED MEDICAL COSTS AND GLYCEMIC CONTROL- A LONGITUDINAL ANALYSIS

    May 1, 2005, 00:00

  • PCV1 COMPARISON OF ALTERNATIVE STRATEGIES FOR THE DIAGNOSIS OF ACUTE CARDIAC ISCHEMIA IN EMERGENCY DEPARTMENTS- STANDARD OF CARE VERSUS BMIPP

    May 1, 2005, 00:00

  • PDB15 DIABETIC RETINOPATHY MODELING-A COST-EFFECTIVENESS OF VARYING SCREENING INTERVALS IN TYPE-2 DIABETES MELLITUS IN THAILAND

    May 1, 2005, 00:00

  • CS4 COST-UTILITY OF CATHETERABLATION FOR FIRST-LINE TREATMENT OF ATRIAL FLUTTER

    May 1, 2005, 00:00

  • PINI6 COST-UTILITY OF CHRONIC HEPATITIS 'C' TREATMENT WITH THYMOSIN ALPHA I IN MEXICO

    May 1, 2005, 00:00

  • PIN27 PROSPECTIVE OBSERVATIONAL STUDY OF PATIENT REPORTED OUTCOMES FORAZITHROMYCIN VS. USUAL CARE IN THE TREATMENT OF ACUTE BACTERIAL EXACERBATIONS OF CHRONIC BRONCHITIS

    May 1, 2005, 00:00

  • PUK16 DOSING PATTERNS OF ERYTHROPOIETIC AGENTS IN ELDERLY PATIENTS WITH CHRONIC KIDNEY DISEASE

    May 1, 2005, 00:00

  • PGI17 TEGASEROD SIGNIFICANTLY IMPROVES QUALITY OF LIFE IN PATIENTS WITH IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C)

    May 1, 2005, 00:00

  • CS8 ECONOMIC EVALUATION OF ONDANSETRON VERSUS DIMENHYDRINATE FOR PREVENTION OF POSTOPERATIVE VOMITING IN CHILDREN

    May 1, 2005, 00:00

  • PNL14 IMPACT OF MIGRAINE FREQUENCY ON HEALTH UTILITIES

    May 1, 2005, 00:00

  • RS3 ESTIMATING THE COST-EFFECTIVENESS OF FLUTICASONE PROPIONATE FORTREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE

    May 1, 2005, 00:00

  • PHPI8 THE INFLUENCE OF DRUG COPAY CHANGE ON DRUG UTILIZATION- THE CASE OF SMALL-FIRM EMPLOYEES IN CALIFORNIA

    May 1, 2005, 00:00

  • PCN23 RELIABILITY OF SPANISH-LANGUAGE HUI MEASUREMENTS IN SURVIVORS OF CANCER IN CHILDHOOD-AGREEMENT BETWEEN PATIENTS, PARENTS, AND PHYSICIANS

    May 1, 2005, 00:00

  • PSM3 CONFIRMATORY VALIDATION OF THE BRIEF QUESTIONNAIRE OF SMOKING URGES

    May 1, 2005, 00:00

  • PAS5 DRUG COST ANALYSIS OF TREATMENT FOR ASTHMA OUTPATIENTS IN TAIWAN

    May 1, 2005, 00:00

  • PMH18 AN EXPLORATORY STUDY TO DEVELOP A MODEL OF QUALITY OF LIFE FOR BIPOLAR DISORDER

    May 1, 2005, 00:00

  • PCN11 THE COST OF CANCER IN KOREA- 1999-2003

    May 1, 2005, 00:00

  • PMH55 CLASSIFYING ANTIPSYCHOTIC ADHERENCE USING LATENT CLASSES ANALYSIS- CHARACTERISTICS OF NON-ADHERENT CASEMIX IN THE CALIFORNIA MEDICAID (MEDICAL) PROGRAM

    May 1, 2005, 00:00

  • PIN18 ESTIMATES OF HEALTH CARE COSTS FOR LAMIVUDINE-REFRACTORY CHRONIC HEPATITIS B (CHB) PATIENTS

    May 1, 2005, 00:00

  • PCV6 LONG-TERM COST-EFFECTIVENESS OF EARLY AND SUSTAINED DUAL ORAL ANTIPLATELET THERAPY WITH CLOPIDOGREL FOLLOWING PERCUTANEOUS CORONARY INTERVENTION (CREDO TRIAL)- A FOUR-EUROPEAN COUNTRY ANALYSIS

    May 1, 2005, 00:00

  • POS5 POST-OSTEOPOROTIC FRACTURE DRUG TREATMENT FOR OSTEOPOROSIS IN NURSING HOME ELDERLY

    May 1, 2005, 00:00

  • PIH9 MORAL HAZARD AND PRESCRIPTION DRUG USE AMONG NON-INSTITUTIONALIZED ELDERLY MEDICARE BENEFICIARIES

    May 1, 2005, 00:00

  • PHP5 TOOLS TO INCREASE THE APPROPRIATENESS OF ALBUMIN UTILIZATION IN AN ITALIAN COMMUNITY HOSPITAL

    May 1, 2005, 00:00

  • PCV25 COST EFFECTIVENESS OF ATORVASTATIN (LIPITOR) AS SINGLE THERAPY AND DUAL THERAPY WITH EZETIMIBE (ZETIA)

    May 1, 2005, 00:00

  • PCN25 RELIABILITY AND VALIDITY OF BRAZILIAN PORTUGUESE HEALTH UTILITIES INDEX (HUI) QUESTIONNAIRES FOR ASSESSING THE HEALTH STATUS OF SURVIVORS OF CHILDHOOD CANCER

    May 1, 2005, 00:00

  • DB8 THE IMPACT OF GLYCEMIC CONTROL ON THE INCIDENCE OF DIABETIC COMPLICATIONS

    May 1, 2005, 00:00

  • PMH47 USE AND COST OF POLYPHARMACY IN SCHIZOPHRENIA- DATA FROM A RANDOMIZED, DOUBLE-BLIND STUDY OF RISPERIDONE AND QUETIAPINE

    May 1, 2005, 00:00

  • PNL31 CLINICAL PRIOR AUTHORIZATION PROGRAM- A STRATEGY FOR CONTROLLING DRUG EXPENDITURES AMONG PATIENTS WITH INSOMNIA

    May 1, 2005, 00:00

  • PHPI9 MEDICATION NEEDS OF ELDERLY INDIVIDUALS WITHOUT PRESCRIPTION DRUG COVERAGE

    May 1, 2005, 00:00

  • PCN9 THE COST-EFFECTIVENESS OF HERCEPTIN IN ADJUVANT SETTING- THE HERA TRIAL

    May 1, 2005, 00:00

  • PIN15 IMPACT OF COMPLICATED SKIN AND SOFT TISSUE INFECTIONS ON INPATIENT COSTS FOR AN ACADEMIC MEDICAL CENTER

    May 1, 2005, 00:00

  • PIN21 AWARENESS AND KNOWLEDGE OF HPV AMONG UNIVSERSITY STUDENTS ATTENDING AN HBCU

    May 1, 2005, 00:00

  • PSM1 DEVELOPING MARKOV-MODEL INCLUDING TOBACCO-ASSOCIATED DISEASES TO EVALUATE SMOKING CESSATION THERAPY IN JAPAN

    May 1, 2005, 00:00

  • PSM2 CONFIRMATORY FACTOR ANALYSIS AND RELIABILITY OF THE 'SMOKING EFFECTS INVENTORY'

    May 1, 2005, 00:00

  • PSR3 THE EVALUATION OF HEALTH RELATED UTILITY (EQ5D INDEX) AND RESOURCE USE IN PATIENTS WITH STROKE COMPLICATED BY UPPER AND LOWER LIMB SPASTICITY

    May 1, 2005, 00:00

  • PHP47 COST-MINIMIZATION ANALYSIS OF SEROLOGIC SCREENING POLICY OPTIONS FOR US ARMY ACCESSION IMMUNIZATIONS

    May 1, 2005, 00:00

  • PIN6 ECONOMIC EVALUATION OF VACCINATION AGAINST STREPTOCOCCUS PNEUMONIAE IN GERMANY INCLUDING HERD IMMUNITY EFFECTS

    May 1, 2005, 00:00

  • PDB6 TREATMENT PATTERNS IN MANAGEMENT OF TYPE-2 DIABETES WITH CONCURRING COMORBIDITIES

    May 1, 2005, 00:00

  • PEY4 A COST-BENEFIT ANALYSIS OF AN APODIZED DIFFRACTIVE MULTIFOCAL INTRA-OCULAR LENS BASED ON WILLINGNESS-TO-PAY IN CATARACT PATIENTS

    May 1, 2005, 00:00

  • PIN9 EXPLORING THE COST-EFFECTIVENESS OF AN IMMUNISATION PROGRAMME FOR ROTAVIRUS GASTROENTERITIS IN THE UNITED KINGDOM

    May 1, 2005, 00:00

  • Comments to the Editor on “Outcomes and Costs of Risperidone versus Olanzapine in Patients with Chronic Schizophrenia or Schizoaffective Disorders- A Markov Model”

    Mar 1, 2005, 00:00

  • Validation of the Restless Legs Syndrome Quality of Life Questionnaire

    Mar 1, 2005, 00:00

  • Using Multiple Anchor- and Distribution-Based Estimates to Evaluate Clinically Meaningful Change on the Functional Assessment of Cancer Therapy-Biologic Response Modifiers (FACT-BRM) Instrument

    Mar 1, 2005, 00:00

  • The Translation and Cultural Adaptation of Patient-Reported Outcome Measures

    Mar 1, 2005, 00:00

  • Cardiac Resynchronization Therapy (CRT) in Heart Failure—A Model to Assess the Economic Value of this New Medical Technology

    Mar 1, 2005, 00:00

  • Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-Reported Outcomes (PRO) Measures- Report of the ISPOR Task Force for Translation and Cultural Adaptation

    Mar 1, 2005, 00:00

  • Comments on the ISPOR Task Force Report on Translation and Adaptation of Outcomes Measures- Guidelines and the Need for More Research

    Mar 1, 2005, 00:00

  • The Economic Burden of Anemia in Cancer Patients Receiving Chemotherapy

    Mar 1, 2005, 00:00

  • Comparing the Discriminative Validity of Two Generic and One Disease-Specific Health-Related Quality of Life Measures in a Sample of Patients with Dry Eye

    Mar 1, 2005, 00:00

  • Excess Mortality, Length of Stay, and Costs Associated with Serious Fungal Infections among Elderly Cancer Patients- Findings from Linked SEER-Medicare Data

    Mar 1, 2005, 00:00

  • Cost-Effectiveness of Recombinant Human Erythropoietin for Reducing Red Blood Cells Transfusions in Critically Ill Patients

    Mar 1, 2005, 00:00

  • Needs-Based Health-Related Quality of Life Measurement- New Wine in Old Bottles?

    Jan 1, 2005, 00:00

  • Needs-Based Quality of Life (QoL)- More Clarity than Claret!

    Jan 1, 2005, 00:00

  • Variability of Cost-Effectiveness Estimates for Pharmaceuticals in Western Europe- Lessons for Inferring Generalizability

    Jan 1, 2005, 00:00

  • Growth and Quality of the Cost–Utility Literature, 1976–2001

    Jan 1, 2005, 00:00

  • An Evaluation of Managing and Educating Patients on the Risk of Glucocorticoid-Induced Osteoporosis

    Jan 1, 2005, 00:00

  • Effect of Outpatient Treatment of Febrile Neutropenia on the Risk Threshold for the Use of CSF in Patients with Cancer Treated with Chemotherapy

    Jan 1, 2005, 00:00

  • Some Considerations for the Interpretation of Health-Related Quality of Life Data

    Jan 1, 2005, 00:00

  • Probabilistic Analysis of Cost-Effectiveness Models- Statistical Representation of Parameter Uncertainty

    Jan 1, 2005, 00:00

  • Collection of Health-Economic Data Alongside Clinical Trials- Is There a Future for Piggyback Evaluations?

    Jan 1, 2005, 00:00

  • Development and Initial Validation of an Instrument to Measure Physician–Pharmacist Collaboration from the Physician Perspective

    Jan 1, 2005, 00:00

  • An Assessment of the Impact of Informative Dropout and Nonresponse in Measuring Health-Related Quality of Life Using the EuroQol (EQ-5D) Descriptive System

    Jan 1, 2005, 00:00

  • Probabilistic Markov Model to Assess the Cost-Effectiveness of Bronchodilator Therapy in COPD Patients in Different Countries

    Jan 1, 2005, 00:00

  • Thresholds in Cost-Effectiveness Analysis—More of the Story

    Jan 1, 2005, 00:00

  • PCV30 COST-EFFECTIVENESS OF N-TERMINAL PRO-BRAIN NATRIURETIC PEPTIDE IN THE DIAGNOSTIC ASSESSMENT AND MANAGEMENT OF PATIENTS WITH DYSPNEA IN THE EMERGENCY DEPARTMENT

    Nov 1, 2004, 00:00

  • NP3 A COST-UTILITY MODEL OF TREATMENT OF NEWLY DIAGNOSED EPILEPSY IN GERMANY COMPARING TOPIRAMATE, CARBAMAZEPINE AND VALPROATE

    Nov 1, 2004, 00:00

  • PMC18 STATISTICAL ISSUES IN DISCRETE CHOICE MODELLING

    Nov 1, 2004, 00:00

  • PHP10 EMERGENCY DEPARTMENT VISITS FOR INJURIES RESULTING FROM BICYCLE ACCIDENTS- TIME, TYPE AND COST OF INJURY

    Nov 1, 2004, 00:00

  • PIN13 ECONOMIC EVALUATION OF VORICONAZOLE IN THE TREATMENT OF INVASIVE ASPERGILLOSIS IN GERMANY

    Nov 1, 2004, 00:00

  • PCV61 THE USE OF INTERNET-BASEDTECHNOLOGYTO ASSESS MEDICATION ADHERENCE IN PATIENTS WITH HYPERTENSION AND TO PROVIDE INTERACTIVE HEALTH INFORMATION

    Nov 1, 2004, 00:00

  • PCV42 PUBLIC HEALTH AND ECONOMIC IMPACTS OF RAISING THE LEGAL SMOKING AGE IN CALIFORNIA

    Nov 1, 2004, 00:00

  • PNL27 MAPPING THE INTERNATIONAL RESTLESS LEGS SYNDROME RATING SCALE (IRLS) TO THE EQ-5D BY FOUR CLINICIANS

    Nov 1, 2004, 00:00

  • PUK8 2-HOUR POST DOSE (C2) MONITORING VERSUS TROUGH (C0) MONITORING OF NEORAL- AN ECONOMIC EVALUATION

    Nov 1, 2004, 00:00

  • PUK18 VALIDATION OF A PATIENT-ADMINISTERED QUESTIONNAIRE TO MEASURE ACTIVITY IMPAIRMENT AS A RESULT OF UNCOMPLICATED URINARY TRACT INFECTION- THE ACTIVITY IMPAIRMENT ASSESSMENT (AIA)

    Nov 1, 2004, 00:00

  • PDB5 COMMUNITY EFFECTIVENESS OF DISEASE MANAGEMENT PROGRAMS IN GERMANY

    Nov 1, 2004, 00:00

  • PUK10 A HEALTH ECONOMIC EVALUATION OF 6 MONTHS ALFUZOSIN TREATMENT IN THE MANAGEMENT OF ACUTE URINARY RETENTION

    Nov 1, 2004, 00:00

  • PCV3 TIME TO LDL-CHOLESTEROL GOAL ATTAINMENT IN SPAIN

    Nov 1, 2004, 00:00

  • PES1 ASSOCIATION BETWEEN DIMINISHED ACTIVITY OF DAILY LIVING AND VISUAL IMPAIRMENT IN SUBJECTS LIVING IN THE COMMUNITY- RESULTS FROM A FRENCH NATIONAL SURVEY

    Nov 1, 2004, 00:00

  • PAR2 THE TOTAL COST OF TREATMENT AND THE COST-EFFECTIVENESS OFVALDECOXIBVS DICLOFENAC IN THE TREATMENT OF PATIENTS WITH OSTEOARTHRITIS (OA) OF THE HIP AND/OR KNEE

    Nov 1, 2004, 00:00

  • PCNI2 COST EFFECTIVENESS OF AN ASPIRIN CHEMOPREVENTION AND/OR COLONOSCOPIC SURVEILLANCE IN THE COLORECTAL CANCER

    Nov 1, 2004, 00:00

  • PCVI6 EVOLUTION OF PRESCRIPTIONS AND DRUG COSTS IN HYPERTENSION-RESULTS FROM A DATABASE FOLLOW-UP STUDY

    Nov 1, 2004, 00:00

  • PUK13 LOWER MENTAL HEALTH SCORES MEASURED USING THE SF-36 HEALTH SURVEY IS AN INDEPENDENT PREDICTOR OF MORTALITY IN YOUNGER PATIENTS RENAL REPLACEMENT THERAPY

    Nov 1, 2004, 00:00

  • PUK16 VALIDATION OF TWO QUESTIONNAIRES ON SYMPTOMS AND QUALITY OF LIFE IN ITALIAN WOMEN WITH LUTS- THE FLOW STUDY

    Nov 1, 2004, 00:00

  • PHP8 ECONOMIC EVALUATION BETWEEN ALTERNATIVE PATTERNS OF OUTPATIENT CARE IN GREECE- THE CASE OF IKA INSURANCE FUND

    Nov 1, 2004, 00:00

  • PHP34 ENTERAL FEEDING IN THE COMMUNITY- A STUDY OF HEALTH ECONOMIC OUTCOMES USING THE GENERAL PRACTICE RESEARCH DATABASE (GPRD)

    Nov 1, 2004, 00:00

  • Author Index, Volume 7

    Nov 1, 2004, 00:00

  • HP2 EVALUATION OF CONDITIONAL REIMBURSEMENT AS A POLICY-INSTRUMENT

    Nov 1, 2004, 00:00

  • CN3 COST-EFFECTIVENESS OF IMATINIB VERSUS INTERFERON (IFN-a) PLUS LOW-DOSE CYTARABINE (ARA-C) FOR NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML) IN THE THE NETHERLANDS

    Nov 1, 2004, 00:00

  • PDB29 THERAPY CHANGE AND PROGRESSION TO INSULIN USE AMONG TYPE-2 DIABETIC PATIENTS NEWLY TREATED WITH SULFONYLUREA (SU) OR METFORMIN (MF) MONOTHERAPY

    Nov 1, 2004, 00:00

  • PHP39 SELF-EFFICACY AND ACADEMIC ACHIEVEMENT OF THE FIFTH YEAR PHARMACY STUDENTS OF CHULALONGKORN UNIVERSITY, 2003

    Nov 1, 2004, 00:00

  • PES16 SCALING PROPERTIES OF THE DERMATOLOGY LIFE QUALITY INDEX (DLQI)

    Nov 1, 2004, 00:00

  • PBR9 ASSESSING HEALTH-RELATED QUALITY OF LIFE IN ROMANIAN HAEMOPHILIACS

    Nov 1, 2004, 00:00

  • PNL4 NEW LEVODOPA/CARBIDOPA/ENTACAPONE (STALEVO) RESULTS IN BETTER QUALITY OF LIFE FOR PARKINSONS DISEASE PATIENTS AND SAVES COSTS TO THE SOCIETY

    Nov 1, 2004, 00:00

  • PRS8 IMPACT ON USE AND COST OF MEDICINES OF EXPANDED DRUG COVERAGE VIA POSITIVE LIST IN THE PHILIPPINES

    Nov 1, 2004, 00:00

  • PHP37 THE INFLUENCE OF CHANGE OF CO-PAYMENT TO THE USE OF ANTIBIOTIC AGENTS

    Nov 1, 2004, 00:00

  • PCV64 FACTORS ASSOCIATED WITH ADHERENCE TO ANTIHYPERTENSIVE MEDICATIONS AMONG VETERANS IN CENTRAL TEXAS

    Nov 1, 2004, 00:00

  • PES18 INTERPRETATION OF SCORES ON THE PSORIASIS INDEX OF QOL (PSORIQOL)

    Nov 1, 2004, 00:00

  • PAR 15 A COMPARISON OF COST OF INFLIXIMAB AND ETANERCEPT IN THE TREATMENT OF RHEUMATOID ARTHRITIS IN ITALY- RESULTS OF THE IERI STUDY GROUP

    Nov 1, 2004, 00:00

  • IN1 IMPACT OF RECENT RITONOVIR RE-PRICING ON COSTEFFECTIVENESS ANALYSIS

    Nov 1, 2004, 00:00

  • POS3 TREATMENT COSTS AND DISEASE BURDEN OF PATIENTS WITH PAGETS DISEASE

    Nov 1, 2004, 00:00

  • CS3 IRBESARTAN IS PROJECTED TO BE COST AND LIFE SAVING COMPARED TO STANDARD BLOOD PRESSURE CONTROL ALONE FOR TREATMENT OF PATIENTS WITH TYPE 2 DIABETES, HYPERTENSION, AND MICROALBUMINURIA IN SPANISH, SWEDISH AND SWISS SETTINGS

    Nov 1, 2004, 00:00

  • PGI9 IS HELICOBACTER PYLORI 'TEST AND TREAT' A COSTEFFECTIVE MANAGEMENT APPROACH FOR PATIENTS WITH TYPICAL REFLUX SYMPTOMS IN A POPULATION WITH A HIGH PREVALENCE OF H. PYLORI INFECTION

    Nov 1, 2004, 00:00

  • PAR26 COST-UTILITY OUTCOMES SIMULATION MODEL FOR OSTEOARTHRITIS (OA) AND RHEUMATOID ARTHRITIS (RA) PATIENTS (COSMO)- DEVELOPMENT AND VALIDATION OF A PHARMACOECONOMIC MODEL

    Nov 1, 2004, 00:00

  • PCV69 ATTITUDES OF OFFICE-BASED PHYSICIANS TOWARDS ANTI-COAGULATION TREATMENT

    Nov 1, 2004, 00:00

  • PMC15 WEIGHING DIAGNOSES IN EVALUATION STUDIES WITH AN APPLICATION TO SYNCOPE

    Nov 1, 2004, 00:00

  • PPN6 BURDEN OF ILLNESS SURVEY IN PATIENTS WITH PAINFUL NEUROPATHIC DISORDER (PNDS) IN GERMANY

    Nov 1, 2004, 00:00

  • PNL10 THE SOCIOECONOMIC IMPACT OF NARCOLEPSY

    Nov 1, 2004, 00:00

  • HP5 WHAT HAPPENS WHEN A PHARMACEUTICAL PRODUCT IS REMOVED OUT OF REIMBURSEMENT?

    Nov 1, 2004, 00:00

  • PES13 A COST MINIMISATION ANALYSIS OF CUSTOM PAK FOR CATARACT SURGERY

    Nov 1, 2004, 00:00

  • PIN14 CALCULATING THE COST OF WOUND CARE IN A COMMUNITY SETTING IN THE UK- AN EXAMPLE USING MODERN WOUND MANAGEMENT DRESSINGS

    Nov 1, 2004, 00:00

  • PDB14 COST-EFFECTIVENESS OF MONO- AND COMBINATION THERAPY WITH PIOGLITAZONE COMPARED TO GLICLAZIDE IN PATIENTS WITH TYPE-2-DIABETES MELLITUS FROM A GERMAN STATUTORY HEALTH CARE PERSPECTIVE

    Nov 1, 2004, 00:00

  • PDB10 THE COST-EFFECTIVENESS OF PIOGLITAZONE IN COMBINATION WITH METFORMIN IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS IN SCOTLAND

    Nov 1, 2004, 00:00

  • MH4 ADHD-RELATED PATIENT AND FAMILY BURDEN- BASELINE RESULTS FROM THE OBSERVATIONAL STUDY ADORE IN GERMANY

    Nov 1, 2004, 00:00

  • PCV65 PERSISTENCE WITH DIFFERENT FORMULATIONS OF THE ANTIHYPERTENSIVE DRUG NIFEDIPINE

    Nov 1, 2004, 00:00

  • PCVI2 SECONDARY PREVENTION AFTER PCI- THE COST-EFFECTIVENESS OF FLUVASTATIN THERAPY IN THE NETHERLANDS

    Nov 1, 2004, 00:00

  • MH3 SCHIZOPHRENIA AND QUALITY OF LIFE ASSESSMENTS

    Nov 1, 2004, 00:00

  • PMC6 THE IMPORTANCE OF ACCOUNTING FOR THE PORTFOLIO EFFECTS IN COST EFFECTIVENESS ANALYSES

    Nov 1, 2004, 00:00

  • PIN28 ASSESSMENT OF BODY CHANGES AND DISTRESS (ABCD) LIPODYSTROPHY QUESTIONNAIRE- CULTURAL ADAPTATION AND PSYCHOMETRIC VALIDATION IN FRENCH

    Nov 1, 2004, 00:00

  • PIN5 MEASURING RESOURCE USE AND DIRECT COSTS IN PATIENTS WITH HEPATITIS C VIRUS MANAGED IN A GASTROENTEROLOGY AND HEPATOLOGY SERVICE

    Nov 1, 2004, 00:00

  • PMH5 FOLLOW-UP OF SCHIZOPHRENIA PATIENTS DISCHARGED FROM PSYCHIATRIC HOSPITALS IN THE UK ON RISPERIDONE OR OLANZAPINE- A TIME-TO-EVENT ANALYSIS

    Nov 1, 2004, 00:00

  • PAR24 RELATIONSHIPS BETWEEN AGE, NUMBER OF PRESCRIPTIONS, AND CO-MORBIDITIES AMONG VA PATIENTS

    Nov 1, 2004, 00:00

  • PES24 IMPACTED CERUMEN- A LITERATURE REVIEW

    Nov 1, 2004, 00:00

  • PIN26 VALIDATION OF 5-ITEM INSTRUMENT FOR ASSESSING SYMPTOM SEVERITY IN PATIENTS WITH ACUTE BACTERIAL SINUSITIS

    Nov 1, 2004, 00:00
  • «
  • 161
  • 162 (current)
  • 163
  • 164
  • 165
  • 166
  • 167
  • 168
  • 169
  • 170
  • »